Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hypogonadism Trial Designs: FDA Panel Favors Symptom Assessments, Fertility Measures

Executive Summary

US advisory committee rejects Repros Therapeutics' proposal for an obesity-related hypogonadism study in which efficacy is based upon testosterone levels and sperm concentrations.

You may also be interested in...



US FDA's New Hypogonadism Guidance Focuses On Non-Testosterone Products

Draft is intended to inform development of non-testosterone products such as aromatase inhibitors or estrogen receptor agonists.

CHMP Readies ‘Outstanding Issues’ Lists For Products Nearing EU Review End

Baxter, Ariad, Diurnal. Kyowa Kirin and AB Science are among the companies that will likely shortly find out what remaining concerns the European Medicines Agency’s key advisory panel, the CHMP, has regarding products of theirs that are under review.

Real World Evidence: ‘Hot Topic’ At US FDA, But Not On Front Burner

Officials are enthusiastic about the possibility of ‘real world evidence’ supporting the regulatory process – but are also eager to tamp down expectations (or fears) that it will make a big difference any time soon.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS119633

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel